Talis Biomedical Corp

Talis Biomedical — Investor Presentation (August 2023)

19 slides from Talis Biomedical's investor presentation, Aug 10, 2023

  1. Slide 1: Talis Biomedical Corporate Presentation August 2023

    Talis Biomedical Corporate Presentation August 2023 Decentralizing Women’s and Sexual Health Testing Exhibit 99.2

  2. Slide 2: Disclaimer

    Disclaimer This presentation may contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “exp

  3. Slide 3: Differentiated to Lead in Significant Untapped Market

    Differentiated to Lead in Significant Untapped Market Advancing health equity and outcomes by delivering accurate infectious disease testing in the moment of need, at the point of care Talis One® System Established innovative, high-performing diagnostic platform at the point of care (POC) PROMISING

  4. Slide 4: Women's/Sexual Health Providers Eager to Test at Point-of-Care

    Women’s/Sexual Health Providers Eager to Test at Point-of-Care INHERENT CLINICAL ADVANTAGE Accurate, immediate treatment reduces empirical prescribing, office visits and patients lost to follow-up ECONOMIC BENEFIT Shifts reimbursement to those providing care COVID ACCELERATED POC PLATFORM ADOPTION C

  5. Slide 5: Large and Growing Market Opportunity

    Large and Growing Market Opportunity 1. BofA Merrill Lynch Global Research, 2015; 2. Talis Bio management estimates; 3. https://health.gov 2018 Tailwinds will accelerate and sustain transition from lab-based testing to POC Incidence of STIs increasing and a growing public-health priority Patients ar

  6. Slide 6: The Talis One System is Designed to Win in POC Market

    The Talis One System is Designed to Win in POC Market SAMPLE PREPARATION Embedded Mechanical Lysis and Nucleic Acid Purification TARGET TURNAROUND Results in <30 Minutes EASE OF USE Designed for CLIA-Waived Settings RELEVANT MENU Actionable Women’s and Sexual Health Tests LOW COST Automated Manufact

  7. Slide 7: Talis One System Technology Overview

    Talis One System Technology Overview

  8. Slide 8: Differentiated to Lead in Women's/Sexual Health Market

    Differentiated to Lead in Women’s/Sexual Health Market POC sample-to-result in <30 minutes Demonstrated ease of use for untrained users1 Integrated DNA/RNA extraction, purification, detection and results management Proven to lyse difficult pathogens in <4 minutes2 Multiple system interface capabilit

  9. Slide 9: Integrated Test Cartridge Enables Sample Prep, Menu Expansion

    On-board Sample Metering Labeled for Human and Instrument Reading Multiplexed Reaction Plugs Mechanical Lysis Easy Sample Loading Solid-Phase Nucleic Acid Purification Closed-System Designed to Reduce Contamination Integrated Test Cartridge Enables Sample Prep, Menu Expansion Self-Contained, Single

  10. Slide 10: Instrument Designed for Ease-of-Use

    Designed for Untrained User Touchscreen Interface Cloud Connectivity Flexible Multiplexing Instrument Designed for Ease-of-Use

  11. Slide 11: Simple Steps to Results in <30 Minutes

    3 Simple Steps to Results in <30 Minutes Results 1 Label with patient ID: Barcode or handwritten 2 Add specimen to cartridge 3 Insert cartridge into instrument

  12. Slide 12: Established Ability to Manufacture at Scale

    >$100M investment in automated manufacturing to deliver 1M tests/month at full scale High speed assembly lines consistently produce cartridges Ability to build instruments efficiently Talis One System performing well in hands of study users Established Ability to Manufacture at Scale Investment in a

  13. Slide 13: Three Tiers of Cartridge Manufacturing Lines

    Three Tiers of Cartridge Manufacturing Lines Provide Flexibility and Stability as Business Scales 1 Assumes one 8-hour shift; 2 Assumes operating all three lines simultaneously 1. Manual 2. Semi Automated 3. Fully Automated Business Use Research & Development Clinical Studies/Early Commercialization

  14. Slide 14: Delivering Clinical and Economic Value to Physicians

    Delivering Clinical and Economic Value to Physicians Minimal capital costs and lower practice overhead with better informed diagnosis and treatment Pricing below established CPT codes Redirects reimbursement from central lab to providers

  15. Slide 15: Not All POC Tests are Created Equal

    Not All POC Tests are Created Equal Does it include sample preparation to ensure lab-quality results? Can it generate a result in less than 30 minutes while the patient is in the office? Can an untrained user operate? Can it deliver multiplex panels with difficult to lyse organisms to meet customer

  16. Slide 16: Prioritizing Assay Development to Accelerate Market Entry

    Confidential. Not for external distribution. Prioritizing Assay Development to Accelerate Market Entry Symptomatic patients Nasopharyngeal swab Ob/Gyn demand confirmed 510(k) pre submission complete Asymptomatic and Symptomatic patients Vaginal swab (self collected) Male urine 510(k) pre submission

  17. Slide 17: Roadmap for Menu Expansion

    Roadmap for Menu Expansion Planning Feasibility Development Clinical Trials Regulatory Submission Respiratory Panel CT/NG/TV HSV 1/2 Vaginal Panel Group B Strep UTI

  18. Slide 18: Talis Biomedical Wins Over Time

    Talis Biomedical Wins Over Time Nascent and growing $3B U.S. market opportunity addressing women’s and sexual health testing Talis One System designed to deliver accuracy, speed, and ease of use High-value efficient product roadmap and clear path to attractive margins Capitalized to execute strategy

  19. Slide 19: Thank you.

    Thank you. 19

Talis Biomedical — Investor Presentation (August 2023) on 6ix